Open AccessDendritic cell-based cancer immunotherapy for colorectal cancer
Author(s) -
Mikio Kajihara,
Kazuki Takakura,
Tomoya Kanai,
Zensho Ito,
Keisuke Saito,
Shiro Takami,
Shigetaka Shimodaira,
Masato Okamoto,
Toshifumi Ohkusa,
Shigeo Koido
Publication year - 2016
Publication title -
world journal of gastroenterology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v22.i17.4275
Subject(s) - medicine , immunotherapy , colorectal cancer , cancer , oncology , cancer immunotherapy , clinical trial , immune system , immunology
Colorectal cancer (CRC) is one of the most common cancers and a leading cause of cancer-related mortality worldwide. Although systemic therapy is the standard care for patients with recurrent or metastatic CRC, the prognosis is extremely poor. The optimal sequence of therapy remains unknown. Therefore, alternative strategies, such as immunotherapy, are needed for patients with advanced CRC. This review summarizes evidence from dendritic cell-based cancer immunotherapy strategies that are currently in clinical trials. In addition, we discuss the possibility of antitumor immune responses through immunoinhibitory PD-1/PD-L1 pathway blockade in CRC patients.